Biodexa shares surge 60.32% after-hours after announcing first European patient enrollment in pivotal Phase 3 Serenta FAP trial.

Biodexa Pharmaceuticals (BDRX) surged 60.32% in after-hours trading following the announcement that it enrolled its first European patients into the pivotal Phase 3 Serenta trial for FAP. This milestone, reported by GlobeNewswire four days prior, marks critical progress in the trial’s global expansion, with the first European site activated 11 days earlier. The company previously secured European CTA approval for the trial in November, setting a timeline for enrollment in Q4 2025. The rally aligns with positive news flow around trial advancements, including the $7 billion addressable market potential for the therapy in the U.S. and Europe.